Dipeptide inhibitors of β-secretase

• US 7,276,484 B2
• Filed: 03/08/2005
• Issued: 10/02/2007
• Est. Priority Date: 06/15/1999
• Status: Expired due to Fees

• Current Assignee: Elan Pharmaceuticals Incorporated (Perrigo Company PLC)
• Original Assignee: Elan Pharmaceuticals Incorporated (Perrigo Company PLC)
• Inventors: Tung, Jay, John, Varghese, Gailunas, Andrea, Fang, Lawrence, Hom, Roy, Mamo, Shumeye S., Guinn, Ashley
• Primary Examiner(s): Lukton; David
• Application Number:
  US11/075,232
• Publication Number:
  US 20050182138A1
• Time in Patent Office: 938 Days
• Field of Search: 514/19, 530/331, 530/332, 562/553
• US Class Current: 514/20.1
• CPC Class Codes: C07K 5/0205 containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
• CPC Class Codes: C07K 5/101 the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Abstract

Dipeptide derived inhibitors of the β-secretase enzyme are provided which are useful in the treatment of Alzheimer'"'"'s disease and other diseases characterized by deposition of Aβ peptide in a mammal. The compounds of the invention provide useful methods of treatment by administration of these inhibitors to reduce Aβ peptide formation and in pharmaceutical compositions.

Claims

1. A method of inhibiting deposition of Aβ

peptide in a mammal comprising administering to a mammal in need thereof an effective amount of a compound of formula 1

2. The method of claim 1 wherein A is selected from biphenyl, 2-phenyl-α

-hydroxytolyl, diphenyl ether and diphenyl ketone.

3. The method of claim 1 wherein A is

4. The method of claim 1 wherein A is

5. The method of claim 1 wherein B is